Aeon Biopharma inc (AEON) - News Archive

In a noteworthy development, AEON Biopharma, Inc. (NYSE: AEON), a clinical-stage biopharmaceutical enterprise focusing on the innovative use of botulinum toxin complexes for various therapeutic treatments, announced a p...

AEON Biopharma Faces NYSE Compliance Challenges Amid Strategic Moves and Ongoing Financial StrugglesIRVINE, Calif. In a recent development that has raised concerns among investors, AEON Biopharma, Inc. (NYSE: AEON), a c...

AEON Biopharma, Inc. Launches Proposed Public Offering Amid FDA Progress and Market Challenges IRVINE, Calif. Jan. 03, 2025 AEON Biopharma, Inc. (NYSE: AEON), a clinical-stage biopharmaceutical company dedicated to adva...

In recent news, AEON Biopharma, a prominent pharmaceutical company, announced a strategic reprioritization to pursue a biosimilar pathway for ABP-450. This shift in focus has come after the preliminary results of AEON B...

Aeon Biopharma Inc, a clinical-stage biopharmaceutical company focused on the development of a botulinum toxin complex for multiple therapeutic indications, has experienced a significant sell-off in its shares recently....

AEON Biopharma Shifts Strategic Focus: Pioneers Biosimilar Pathway for ABP-450 with Proactive Phase 3 Trials and Promising Results AEON Biopharma is set to recalibrate its strategic direction toward developing biosimila...

In recent weeks, AEON Biopharma, Inc. (AEON) has experienced a significant decline, with its stock plummeting by an alarming 64.16%. However, market analysts indicate that this oversold condition may actually signify a...

In recent months, China has witnessed a concerning trend as its domestic investors divert their attention and capital abroad, particularly towards Hong Kong. This behavior, accompanied by a depreciating yuan, reflects a...

In a strategic move aimed at optimizing resources and reducing costs, AEON Biopharma recently announced a reprioritization plan. The company expects its current cash and cash equivalents to be adequate to sustain corpor...

AEON Biopharma, a prominent name in the pharmaceutical sector, recently provided an update concerning its diverse development pipeline. The update explicitly outlines four significant clinical programs, bifurcated into...

This article provides an analysis of the preliminary top-line results from the Phase 2 interim analysis of ABP-450, a drug developed by AEON Biopharma for the preventive treatment of chronic migraine. The trial outcomes...

In an exciting development for the field of migraine treatment, AEON Biopharma recently announced its fourth quarter and full year 2023 financial results along with a successful end-of-Phase 2 meeting with the FDA. The...

AEON Biopharma Streamlines Capital Structure with Strategic Board Appointment and Impressive Financial GrowthAEON Biopharma Inc. has recently made significant strides in simplifying its capitalization structure, with th...

In a groundbreaking presentation at a premier neurotoxin conference, AEON Biopharma unveiled positive clinical and pre-clinical data for their latest development, ABP-450 (prabotulinumtoxinA). The results showcased the...